Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co.'s product categories are: biologics, which include Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and Mepsevii® (vestronidase alfa) for the treatment of Mucopolysaccharidosis VII; small molecules, which includes UX007 for the treatment of long-chain fatty acid oxidation disorders; and gene therapy, which includes DTX301 for the treatment of patients with ornithine transcarbamylase deficiency and DTX401 for the treatment of patients with glycogen storage disease type Ia. We show 32 historical shares outstanding datapoints in our coverage of RARE's shares outstanding history.
Understanding the changing numbers of RARE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like RARE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching RARE by allowing them to research RARE shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
